Skip to main content

Table 3 Reasons for SMC drugs having no NICE designation for EOL

From: Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes

  Number of submissions
No NICE appraisal:
 In development 10
 Suspended 2
 Non-submission by the company 2
 Not scheduled for NICE appraisal 2
NICE agreed to fund without EOL consideration 3
NICE ICER too high regardless of EOL status 2
Appraised by NICE pre-2009 (ie before introduction of EOL criteria) 1
Total 22